Results of two phase 3, placebocontrolled trials were published today in the new england journal of medicine. Riociguat adempas treatments for pulmonary hypertension issued by phas scientific leadership council. Riociguat is a stimulator of guanylate cyclase which causes relaxation of vascular smooth muscle and is used to treat severe pulmonary arterial hypertension. Adempas riociguat dose, indications, adverse effects. It is used to treat two forms of pulmonary hypertension. Riociguat in patients with chronic thromboembolic pulmonary hypertension cteph eas the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Doses of riociguat were increased stepwise, and riociguat was well tolerated up to 2. Riociguat, a soluble guanylate cyclase stimulator, was shown to be a safe and effective treatment for patients with pah in the phase iii patent1 study and the patent2 longterm extension 2, 3. Females must not be pregnant when starting riociguat or become pregnant during treatment. Instruct females to use effective contraception intrauterine device iud, contraceptive implants, tubal sterilization or a combination of methods hormone method with a barrier method or two barrier methods during and for at least a mo following discontinuation of therapy. Pregnancy tests will also be done every month while you take riociguat and for 1 month after you stop taking it.
Adempas bayer for oral treatment of pulmonary arterial hypertension pah and chronic thromboembolic pulmonary hypertension cteph following surgery or when surgery is not an option. Riociguat for pulmonary arterial hypertension and chronic. The studies were carried out in accordance with good clinical practice guidelines and the declaration of helsinki. If you get pregnant or plan on getting pregnant while taking riociguat, call your doctor right away.
In an openlabel trial, riociguat was studied in 23 patients with interstitial lung disease who also had ph with a above 30 mm hg and no more than mild airflow obstruction. Riociguat is the first drug approved by the us food and drug administration for the treatment of both pah and inoperable or persistentrecurrent cteph 17, 22, 23. Riociguat has not been linked to significant serum enzyme elevations during therapy or. Riociguat is a new drug that is approved for pah and cteph based on the evidence generated from two pivotal trials, chest1 and patent1. This product information was approved at the time this auspar was published. Concomitant use with other medicinal products the concomitant use of riociguat with strong multi pathway cytochrome p450 cyp and p. The griphon trial 43 randomized 1156 patients from 39 countries to receive placebo median duration, 64 weeks or selexipag median duration, 71 weeks therapy titrated to the maximal tolerated dose. Vericiguat is currently in late stage clinical development for the treatment of heart failure with reduced and also with preserved ejection fraction hfref and hfpef.
Side effects of adempas riociguat tablets, warnings, uses. In patenti, 443 patients with symptomatic pah 61% idiopathic pah, 25% pah associated with connectivetissue disease were randomly allocated in a 2. Riociguat adempas for pulmonary hypertension the medical. Dose adjustment may be necessary in patients who start or stop smoking during treatment with riociguat see sections 4. Ghofrani ha1, galie n, grimminger f, grunig e, humbert m, jing zc, keogh am, langleben d, kilama mo, fritsch a, neuser d, rubin lj. Riociguat for the treatment of pulmonary hypertension. Riociguat is highly bound to plasma proteins 95% and is metabolized by cyp1a1, cyp3a, cyp2c8 and cyp2j2. The authorized source of trusted medical research and education for the chineselanguage medical community. It has been designated an orphan medicine by the european. Plasma concentrations of riociguat in smokers are reduced compared to nonsmokers. Another new pah medication is riociguat, a guanylate. Riociguat in patients with chronic thromboembolic pulmonary.
Adempas prices, coupons and patient assistance programs. Background riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension. Riociguat for the treatment of chronic thromboembolic pulmonary. Riociguat plasma concentrations directly correlate to hemodynamic parameters such as systemic vascular resistance, systolic blood pressure, pulmonary vascular resistance, and cardiac output. Product information for auspar adempas riociguat bayer australia ltd pm 200307 final 12 june 2014. Chronische tromboembolische pulmonale hypertensie cteph. Riociguat, a member of a new class of compounds soluble guanylate cyclase stimulators, has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic.
Patent1, a randomised double blind trial demonstrated a positive response to riociguat therapy ghofrani et al, 20. The fda approved on tuesday a new drug for pulmonary hypertension. Riociguat in children with pulmonary arterial hypertension pah patentchild the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Riociguat pharmacokinetics absorption bioavailability. Riociguat may also be used for purposes not listed in this medication guide. Adempas riociguat dosing, indications, interactions. Visit to see full safety and prescribing information including boxed warning. Riociguat was well tolerated and improved exercise and functional capacity in patients with pulmonary arterial hypertension pah and inoperable chronic thromboembolic pulmonary hypertension cteph in a 12week phase ii trial.
Adempas riociguat is a member of the vasodilators drug class and is commonly used for pulmonary hypertension. In the new england journal of medicine this week, ghofrani et al. It is a direct sgc stimulator and has shown improvement in the primary end points as measured by 6mwd from shortterm studies, besides other secondary end points. Background the 12week, phase iii pulmonary arterial hypertension sgcstimulator trial patent1 study investigated riociguat in patients with pulmonary arterial hypertension pah. Riociguat has not been linked to significant serum enzyme elevations during therapy or to instances of clinically apparent acute liver injury. Background riociguat, a member of a new class of compounds soluble guanylate cyclase stimulators, has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboe.
There is a potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensive agents. Riociguat is the first drug approved in the new class of sgc stimulators. Pulmonary arterial hypertension in the contemporary era. This indicates that riociguat could be considered as first line therapy for patients. Riociguat for the treatment of chronic thromboembolic. However, as none of the studies compared effectiveness and safety of riociguat to pde5 inhibitor or an era the data is unable to provide.
Riociguat is a firstinclass oral medication that adds to the treatment options for pah. Riociguat is a soluble guanylate cyclase agonist approved by the food and drug administration in 20 for the treatment of pah that was studied in patients with phld. Adempas riociguat is a soluble guanylate cyclase stimulator used to treat adults with two forms of pulmonary hypertension. Riociguat, a soluble guanylate cyclase stimulator under development by bayer, is thought to have vasodilating, antiproliferative, and antifibrotic effects. Here, we present a prospectively planned analysis of the safety and efficacy of riociguat in the subgroup of patients with pah associated with connective tissue disease pahctd. Pulmonary hypertension advisory board title livemedia. Information is based on the united states food and drug administration drug labeling. Pulmonary arterial hypertension associated with congenital heart disease pahchd is a common associated form of pah. Here, we present a prospectively planned analysis of the safety and efficacy of riociguat in the subgroup of patients with pah associated with connective tissue disease. Listing a study does not mean it has been evaluated by. Riociguat therapy for pulmonary hypertension nature.
Riociguat adempas is a firstinclass activator of the soluble form of the enzyme sgc. Riociguat is a member of a new class of therapeutic agents called soluble guanylate cyclase stimulators. Expert, exposure registry riociguat in patients with. Jul 25, 20 riociguat for the treatment of pulmonary arterial hypertension. Effect of riociguat on bone metabolism the safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
Riociguat is an oral medication called a soluble guanylate cyclase stimulator approved for the treatment of pulmonary arterial hypertension pah in world health organization who group 1 patients. Consequently, systemic exposure to riociguat and m1 in the ph population is 2. A proofofconcept study, reported by the university of gie. Riociguat is a drug by bayer that is a stimulator of soluble guanylate cyclase. Nejm journal watch concise summaries and expert physician commentary that busy clinicians need to enhance patient care. Learn about adempas riociguat and the aim patient support program. How adempas works both cteph and pah cause lung blood vessels to narrow. Oct 29, 2014 riociguat adempas, a soluble guanylate cyclase stimulator, is a new, firstinclass drug approved for the treatment of patients with chronic thromboembolic pulmonary hypertension cteph inoperable or persistentrecurrent following surgery or pulmonary arterial hypertension pah. Riociguat appears to be effective and well tolerated. The clinical development of sgc modulators, riociguat and. Listing a study does not mean it has been evaluated by the u. A read is counted each time someone views a publication summary such as the title, abstract, and list of authors, clicks on a figure, or views or downloads the fulltext.
Clearance of riociguat in subjects with ph is about half that in healthy subjects 1. Haemodynamic effects of riociguat in inoperablerecurrent. The goal of this therapy for pah is to improve exercise ability, who functional class and delay clinical worsening. Adempas is a prescription medicine used to treat adults with. This adempas price guide is based on using the discount card which is accepted at most u. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Riociguat can cause serious birth defects if taken during pregnancy. Riociguat in children with pulmonary arterial hypertension.
Riociguat is also used to treat chronic thromboembolic pulmonary hypertension cteph. Riociguat is used to treat pulmonary arterial hypertension pah. Riociguat is a cardiovascular agent that is fda approved for the treatment of persistent,recurrent chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. Effect of riociguat on bone metabolism full text view. For this reason, females who can become pregnant must have regular testing to insure they are not pregnant, or become pregnant during therapy or within one month of stopping riociguat. Riociguat definition of riociguat by medical dictionary. Nov 19, 2019 a pregnancy test will be done before starting riociguat to show that you are not pregnant. Riociguat for the treatment of pulmonary arterial hypertension. Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension. Riociguat is a soluble guanylate cyclase stimulator that promotes vasodilation in the pulmonary circulation. Bayer developed it for chronic thromboembolic pulmonary hypertension, or cteph, and pulmonary arterial hypertension, or pah. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Pharmacology pharmacodynamic properties riociguat is a stimulator of soluble guanylate cyclase sgc, an enzyme found in most. With regard to the articles on the chronic thromboembolic pulmonary hyper tension soluble guanylate cyclasestimulator.
A not so new drug landscape for pulmonary arterial hypertension john ryan, md just in the past several months, the fda has approved three new medications for pulmonary arterial hypertension pah. Riociguat represents a new class of medicines available for pulmonary hypertension and. Riociguat is an oral medication called a soluble guanylate cyclase stimulator approved for the treatment of pulmonary arterial. Any printed copies of this document are not controlled. The new engl and journal of medicine n engl j med 369. You must be registered in the program and understand the risks and benefits of riociguat. It is the first drug to be approved for treatment of cteph. Riociguat, as a sgc stimulator, has been approved for the treatment of pulmonary arterial hypertension pah, but enthusiasm on discovery of sgc modulators continues for their potential new. Initial trials of riociguat, an oral medication that stimulates limited options are available for treating patients with pulmonary hypertension. Adempas riociguat is an approved treatment for the symptoms of pulmonary hypertension. Expert, exposure registry riociguat in patients with pulmonary hypertension expert the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. In the treatment of inoperable cteph, riociguat is the only drug to consistently demonstrate clinical efficacy in a placebocontrolled study.
Bayer healthcares riociguat brand name adempas was approved for two indications. Pah is a chronic disorder in which morbidity and mortality remain high despite the availability of medical therapies. Feb 18, 2020 riociguat can improve your ability to exercise and help prevent pah from getting worse. It is also the only agent approved for cteph, albeit in select patients. Riociguat is available to women only under a special program. The fda has approved the sgc stimulator riociguat rye oh sig ue at. Riociguat s ongoing clinical development program includes phiip and diffuse cutaneous sclerodermia, as well as an exploratory study in cystic fibrosis. The scottish medicines consortium has advised december 2014 that riociguat adempas is accepted for restricted use within nhs scotland for the treatment of chronic thromboembolic pulmonary hypertension in adults for whom a phosphodiesterase type5 inhibitor is inappropriate, not tolerated, or ineffective, and should only be prescribed by specialists in the scottish pulmonary vascular unit. New drug for pulmonary hypertension approved by fda. Riociguat, a soluble guanylate cyclase sgc stimulator, is approved for the treatment of both pah and inoperable cteph or persistentrecurrent cteph after pea.
297 676 621 1273 947 649 1404 837 1368 1525 318 154 1302 19 1550 44 218 1186 1570 646 1526 1392 372 23 265 509 80 228 714